MHC molecules bind and present (foreign) peptide antigens. Under normal conditions MHC molecules are loaded with peptides derived from self proteins that elicit no immune responses. It is now well established, however, that peptides derived from particular proteins, for example tissue-specific proteins, can form the target for CD4' and CD8' T-cells. Whereas this can be beneficial in the case of responses directed to proteins preferentially expressed in tumour cells, in other cases this may lead to autoimmune disease, since many autoimmune diseases are believed to be caused by unwanted T-cell reactivity towards autoantigens.
In recent years much progress has been made in the identification of MHC class-I-bound peptides that are the target of cytotoxic T-cells. Most autoimmune diseases, however, are linked to the expression of particular MHC class I1 gene products, suggesting that such class I1 molecules present peptides derived from autoantigens to CD4' autoreactive T-cells. Many naturally processed, class-11-bound peptides have been identified in recent years, most of which were fragments of either cytosolic or membranebound proteins. Only occasionally the source proteins for such peptides were endocytosed, exogenous antigens. Since autoreactive T-cells may also be specific for peptides derived from such exogenous antigens, we have developed a new delivery system that allows increased presentation of peptides from exogenous antigens by HLA class I1 molecules.
A rate-limiting step in the formation of intracellular complexes between class I1 molecules and peptides derived from exogenous antigens is the uptake of such antigens and their transport to the MHC class I1 loading compartment (MIIC). Certain types of professional antigen-presenting cells, including macrophages and certain dendritic cells, express mannose receptors. These mannose receptors specifically bind to mannosylated compounds and mediate their internalization. Since mannosylated proteins are common to various types of pathogens but not to self proteins, this represents an early phase of self/non-self discrimination.
We have investigated the intracellular route of this mannose receptor and its mannosylated ligand in cultured human monocyte-derived dendritic cells. We observed that the endocytosis of the mannose receptor and its ligand takes place via small coated vesicles, whereas a nonmannosylated antigen was taken up in larger vesicles, most likely macropinosomes. After internalization, both the mannose receptor, its ligand and the non-mannosylated antigen co-localized in the larger vesicles, suggesting that coated vesicles deliver their contents to the larger vesicles. After approx. 10 min, the manno-
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The Molecular Biology of Autoantigens sylated and non-mannosylated antigens were found in vesicles that contained markers typical for the MIIC and lysosomes. The mannose receptor itself, however, was never found in the MIIC, suggesting that it releases its ligand in an earlier endosomal structure and recycles back to the membrane. Moreover, we observed that mannosylation of peptide antigens led to an enhanced potency to stimulate HLA class I1 restricted, peptide-specific T-cells. Depending on the peptide used, 300-10000-fold less of a mannosylated peptide was required to stimulate these T-cells compared with a non-mannosylated peptide. These results indicate that the mannose receptor mediates internalization of ligand that is followed by transport to the MIIC, and that this leads to strongly enhanced antigen presentation by HLA class I1 molecules. These results may be of relevance for the design of improved vaccination strategies and the delivery of MHC-blocking peptides. They may also be useful to enhance antigen uptake by professional antigen-presenting cells, which could facilitate the identification of naturally processed, HLA-class-11-bound peptides derived from exogenous antigens.
Introduction
Studying autoimmune responses in man is not an easy task. Because there are few clues to how they are initiated, realistic animal models are rare. Furthermore, few of the target molecules are well characterized; in many of the best known cases they are sparse and can be produced in any quantity only by artificial manipulations in vim. A good example is the acetylcholine receptor (AChR) of muscle, which is attacked by the pathogenic autoantibodies in myasthenia gravis (MG). These heterogeneous high-affinity IgGs reduce AChR numbers partly by activating complement and also by accelerating receptor degradation [ 1, 2] . One important goal of research is to develop methods for selectively preventing or halting anti-AChR antibody production without global immunosuppression and its undesirable side-effects. In experimental models this response clearly depends on specific helper T-cells [3, 4] ; these seem promising targets for such immunotherapy because they may prove to be more restricted than the autoantibodies which might, in any case, block specific Abbreviations used: AChR, acetylcholine receptor; APC, antigen-presenting cells; MG, myasthenia gravis; Mabs, mouse monoclonal antibodies; TCR, T-cell receptor(s) .
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immunotherapeutic agents in the circulation. Hence one of the first critical issues is the heterogeneity of the pathogenic T-cells; this has been studied by a variety of approaches.
The AChR antigen, the antibodies and the myasthenic patients
Motor endplates cover a tiny fraction of the muscle surface but the AChRs are very concentrated there. They consist of four evolutionarily related subunits, u (represented twice), p, 6 and E , of 50-55 kDa. Each has about 210 amino acid residues in its highly folded extracellular domain, followed by four transmembrane segments; there is a cytoplasmic loop of roughly 100 residues between the last two [ S ] . Together they form an ion channel that opens in response to the binding of transmitter to external sites on the a/6 and a / & interfaces [6] . The u subunits are thought to be immunodominant in the T-cell response [7] , and the a67-76 sequence also makes a major contribution to the main immunogenic region that is recognized by many of the patients' autoantibodies [8]. However, these only bind minimally to unfolded subunits, even though the isolated cytoplasmic sequence in particular can readily evoke antibodies (in animals) that cross-react with whole AChR [9] . Thus the patients' specific B-cells must presumably also bind the AChR in its native conforma-
